Ken Griffin Design Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $5.88 $3,828 - $7,056	1,200 Added 109.09%	2,300 $12,000
Q2 2024 Aug 14, 2024	BUY	$3.23 - $4.77 $3,230 - $4,770	1,000 Added 1000.0%	1,100 $3,000
Q1 2024 May 15, 2024	SELL	$2.27 - $4.03 $5,675 - $10,075	-2,500 Reduced 96.15%	100 $0
Q4 2023 Feb 14, 2024	SELL	$1.99 - $2.76 $9,353 - $12,971	-4,700 Reduced 64.38%	2,600 $6,000
Q3 2023 Nov 14, 2023	BUY	$2.05 - $8.14 $12,504 - $49,654	6,100 Added 508.33%	7,300 $17,000
Q2 2023 Aug 14, 2023	SELL	$4.99 - $7.64 $24,451 - $37,436	-4,900 Reduced 80.33%	1,200 $7,000
Q1 2023 May 15, 2023	SELL	$5.5 - $9.77 $877,250 - $1.56 Million	-159,500 Reduced 96.32%	6,100 $35,000
Q4 2022 Feb 14, 2023	BUY	$7.86 - $17.2 $50,304 - $110,080	6,400 Added 4.02%	165,600 $1.7 Million
Q3 2022 Nov 14, 2022	BUY	$14.09 - $25.57 $380,430 - $690,390	27,000 Added 20.42%	159,200 $2.66 Million

102

31M

2.3K

16.5K

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $349M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.